Curex vs NiceRx
Two GLP-1 providers, one scoreboard. We put Curex and NiceRx head-to-head on the published Brief Score — the same six factors, scored the same way.
Curex
FDA warning letter, September 2025 — issued to Curex. See the FDA's warning letter database.
The verdict
Too close to call on the Brief Score.
Curex and NiceRx are level at 86/100. The scores won't separate them, so the pick comes down to fit: Curex for readers who want one predictable price across sema and tirz from an accredited, nationwide provider. NiceRx for readers who want a longer-tenured, accredited name over an unknown newcomer.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Curex | NiceRx | |
|---|---|---|
| Brief Score | 86/100 (B) | 86/100 (B) |
| Semaglutide | $199/mo | $199/mo |
| Tirzepatide | $199/mo | $299/mo |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Injection only |
| On the tracker | Stableprice stable | Stableprice stable |
Curex: Flat $199 on both molecules; LegitScript-certified and nationwide.
NiceRx: $199 sema / $299 tirz nationwide; LegitScript-certified, established operator.
● Not sold on either?
CoreAge Rx tops the whole ranking at 94/100.
One price on both molecules that does not climb as you titrate — but the headline $99 and $149 are annual-plan rates, paid in full up front.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.